Search Bar & Filters
Found 165 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of EscharEx EX-03 5% formulation compared to a placebo in the treatment of Venous Leg Ulcers VLU. This study involves adults with VLU wounds between 2 cm and 25 cm in size, with wound duration from 4 weeks to 12 months. It aims to assess how well EscharEx helps with debridement and wound bed preparation. Participants will be randomly assigned to receive either EscharEx, a sterile powder containing proteolytic enzymes enriched in bromelain, or a placebo gel without the active enzyme. The powder is mixed with sterile water to form a gel that is applied to the wound area. The study includes several periods a screening period with two visits, a daily treatment period of up to eight daily applications over two weeks, followed by weekly wound management visits for up to 12 weeks, and an optional wound closure confirmation period of up to two weeks. After wound closure, participants enter a 12-week monthly visit period to monitor wound closure durability. During the study, participants undergo clinical assessments of wound debridement and closure, including visual evaluations after each application and over the follow-up periods. Researchers will measure the incidence of complete debridement, time to wound closure, and healthy tissue development. Safety and wound healing progress are monitored throughout. The total participation can last up to 29 weeks, with regular visits to ensure detailed monitoring of wound status and treatment effects.
Actively Recruiting
Researchers are studying an experimental drug called REGN10597, given alone or with another drug called cemiplimab, in adults with advanced solid tumors such as melanoma and clear-cell renal-cell carcinoma. This Phase 12a trial aims to evaluate how safe, tolerable, and effective these study drugs are in treating cancers that have spread in the body. The study also explores side effects, drug levels in the blood, and whether the body produces antibodies against the drugs that might affect their activity or cause side effects. Participants receive REGN10597 alone or combined with cemiplimab in different dose levels to find the best dose for future studies. The study includes dose escalation and dose expansion phases, with separate groups for melanoma and renal-cell carcinoma patients. Dosing and administration follow the study protocol, and participants may have biopsies at screening and other times for research purposes. During the study, participants will be monitored closely for side effects and treatment responses. Researchers assess tumor response using established criteria and track various safety outcomes over approximately six years. Blood samples are collected to measure drug concentrations and antibody development. Participants will have regular visits for evaluations, and their health status will be followed for a long-term period to understand treatment effects and safety.
Actively Recruiting
This research aims to provide continued access to niraparib and to further assess its long-term safety in participants with ovarian or breast neoplasms who are currently receiving niraparib treatment within previous GlaxoSmithKlineTESARO-sponsored studies. It focuses on participants who have completed earlier studies where the primary objectives were met and are judged by their doctors to still benefit from niraparib. The study is a phase 2, open-label extension trial designed to monitor treatment continuation and safety over time. Participants will receive niraparib once daily by mouth, following the same dose and schedule as in their previous parent study. Treatment is organized in 90-day cycles and will continue until disease progression, unacceptable side effects, new anticancer therapy unrelated to the parent study, withdrawal, or other reasons for discontinuation occur. The dosing regimen mirrors what was assigned in the prior study, ensuring consistency for each participant. During the study, participants will have regular evaluations to monitor safety and health status for up to five years. These assessments include tracking adverse events, serious side effects, and specific safety concerns, as well as monitoring physical exams, vital signs, blood tests, and medication use. Participants must comply with scheduled visits and treatments while using effective contraception if of childbearing potential. The study duration and follow-up are designed to gather detailed long-term safety information on niraparib treatment.
Actively Recruiting
Researchers are conducting a master protocol study to evaluate the long-term safety and efficacy of the drug pirtobrutinib in patients who have completed previous clinical studies involving this medication. This study includes participants with chronic lymphocytic leukemia or non-Hodgkin lymphoma and aims to monitor their health over an extended period. The master protocol organizes individual study-specific appendices ISAs representing participants from earlier originator studies. Participants continue to receive pirtobrutinib as they did in their original clinical study, with the drug administered orally. The study allows these individuals to keep taking the treatment or to continue with follow-up visits under this master protocol framework. The study is designed to gather safety and survival data over many years. During the study, participants will be closely monitored for any serious treatment-related side effects, with assessments focused on adverse events occurring from the first dose until shortly after the last dose or when starting a new anticancer therapy. Researchers will also track overall survival for up to 93 months. This long-term follow-up ensures comprehensive safety and health evaluations throughout the participants involvement, which may last several years.
Actively Recruiting
Researchers are conducting a first-in-human, open-label phase 1 study to evaluate the safety, tolerability, pharmacokinetics PK, pharmacodynamics PD, and early anti-tumor effects of EPI-326. This study focuses on patients with locally advanced or metastatic non-small cell lung cancer NSCLC that has an EGFR mutation, as well as patients with head and neck squamous cell carcinoma HNSCC. The investigational drug EPI-326 is a tissue-selective bispecific antibody targeting EGFR-driven cancers. Participants will receive ascending doses of EPI-326 administered by intravenous infusion in a clinical setting. Treatment will continue until disease progression, unacceptable side effects, withdrawal of consent, or study termination. This study is conducted at multiple centers and aims to determine the recommended dose and schedule for EPI-326. During the study, participants will be monitored for safety and tolerability, with blood tests measuring drug concentrations over time. Researchers will assess tumor response and duration of response. The study duration can be up to three years, allowing for comprehensive evaluation. Participants will have regular assessments to track their health status and treatment effects throughout the study period.
Actively Recruiting
Researchers are evaluating PLN-101095 combined with pembrolizumab in adults with advanced or metastatic solid tumors that have progressed despite prior pembrolizumab treatment. This Phase 1a1b open-label study aims to assess the safety, tolerability, pharmacokinetics PK, pharmacodynamics PD, and early signs of antitumor activity of this combination in patients with documented resistance to immune checkpoint inhibitors. The study includes two parts Part 1 involves consecutive dose-escalation cohorts of PLN-101095 at varying doses 250 mg to 2000 mg, administered twice or three times daily combined with pembrolizumab given intravenously every three weeks. Part 2 expands dosing cohorts to evaluate the combination and PLN-101095 monotherapy in specific tumor types, including non-small cell lung cancer, clear cell renal cell carcinoma, and tumor mutational burden-high solid tumors. Participants undergo treatment cycles with regular safety and tumor assessments, including monitoring of side effects and drug levels. Researchers will measure outcomes such as safety and tolerability from first dose through 16 weeks post-treatment, as well as antitumor activity until disease progression or death. The study spans up to several years, with ongoing evaluations to understand the treatments effects and duration of response.
Actively Recruiting
Researchers are conducting a Phase 1, open-label study to evaluate CTX-10726, a new drug given alone to patients with advanced or metastatic cancers including gastroesophageal cancer, hepatocellular carcinoma, endometrial cancer, and renal cell carcinoma. The main goals are to assess the safety, tolerability, immune response, and how the drug moves through the body. The study also looks at early anti-tumor activity to understand its potential effects. Participants receive CTX-10726 through intravenous infusion every two weeks. The study has two parts a Dose Escalation Cohort where different dose levels 0.3 to 10.0 mgkg are tested to identify safe doses, followed by a Dose Expansion Cohort where selected doses from the first part are further evaluated. The Dose Escalation uses a 33 design, and dosing continues with regular infusions during the treatment periods. During the study, participants undergo regular monitoring for side effects and drug effects, including blood tests and imaging to measure tumor response. Researchers measure drug levels in the blood and immune responses. Safety is tracked from the first dose until 30 days after the last dose, with some participants monitored for up to two years. The study includes assessments of tumor size, duration of response, disease control, survival, and detailed pharmacokinetic measurements.
Actively Recruiting
Researchers are studying DB-1303BNT323, a biological drug, in a Phase 12a trial to evaluate its safety and tolerability in adults with advanced or metastatic malignant solid tumors that express HER2. The trial focuses on patients whose tumors are refractory to standard treatments or have no available standard options. This first-in-human study includes both a dose-escalation phase to find the maximum tolerated dose and a dose-expansion phase to further assess safety and explore efficacy in selected tumors. Participants receive DB-1303BNT323 intravenously once every three weeks at various dose levels, including a randomized comparison of doses during some expansion cohorts. Additional treatments may include ritonavir or itraconazole to assess drug interactions, and in some cases, DB-1303BNT323 is combined with Pertuzumab. The study is open-label and multicenter, with dosing continuing according to the protocols schedule. During the trial, participants undergo regular assessments including safety monitoring for adverse events, dose-limiting toxicities, and serious adverse events up to about one year post-treatment. Researchers measure tumor response using RECIST 1.1 criteria and evaluate pharmacokinetics and pharmacodynamics. Organ function, heart performance, and life expectancy are also monitored throughout this period. The estimated study completion is in October 2027.
Actively Recruiting
Researchers are evaluating zanidatamab for the treatment of adults with previously treated solid tumors that show high levels of HER2 protein IHC 3 overexpression. This phase 2, open-label study focuses on participants whose cancers have progressed despite prior systemic treatments and who have no confirmed beneficial treatment options left. Participants receive zanidatamab administered by intravenous infusion. The study includes participants with various HER2-expressing solid tumors, excluding biliary tract cancers. Some cohorts allow prior HER2-targeted therapy, while others do not. Treatment continues with monitoring for up to 2.5 years to evaluate response and safety. During the study, participants undergo regular assessments including tumor evaluations by independent central review and investigator assessment using RECIST 1.1 criteria. Researchers monitor objective response rates, duration and time to response, disease control, progression-free and overall survival, and treatment-emergent adverse events. Blood samples measure zanidatamab concentration and antibody development. Participants are followed for safety and treatment effects for up to 3.5 years.
Actively Recruiting
Researchers are evaluating TJ102, an investigational antibody-drug conjugate ADC, to determine its safety, tolerability, and preliminary effectiveness in adults with advanced or metastatic ovarian cancer or other solid tumors who have exhausted standard treatments. The study aims to find the maximum tolerated dose MTD and the recommended dose for further testing in this patient population. Participants will receive intravenous infusions of TJ102 every three weeks. During the initial dose escalation phase, doses will increase to find the optimal level, followed by a dose expansion phase at the selected dose. The study involves regular tumor imaging to monitor response, blood sampling for drug levels and biomarker analysis, and close monitoring for side effects throughout treatment. Participants will undergo assessments including imaging scans and laboratory tests before and during treatment. Researchers will track adverse events, treatment tolerability, and various pharmacokinetic measurements such as drug concentration and half-life over up to two years. The study also measures anti-drug antibody presence and overall survival outcomes. Total participation may last several years as safety and efficacy are evaluated.
1-10 of 165
1